Collective Defence today announces its formation following the combination of ITC Secure, a leading UK-based cybersecurity services firm and Microsoft Security Solutions Partner, and IronNet, a pioneer in collective defence and network detection technology. The company is headquartered in Luxembourg and operates from offices in the United States, United Kingdom, and Singapore. Collective Defence addresses one of the most pressing security challenges of our time: the escalating threat of hybri...
The Abu Dhabi Autonomous Racing League (A2RL) Drone Championship delivered a decisive test of autonomous and human performance, as Technology Innovation Institute’s TII Racing set the fastest autonomous lap to win the AI Speed Challenge, while a human first-person-view (FPV) pilot, MinChan Kim – World FPV Champion, narrowly claimed victory in the Human vs AI finale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126735530/en/A2RL...
Echoworx, the trusted name in email encryption, is now live on AWS Marketplace—fully deployed on AWS infrastructure. For global businesses, this means securing sensitive communications just got a whole lot easier, starting from purchase. Why AWS Marketplace? Why Now? Echoworx’s mission has always been to make secure communications as easy and accessible as possible. By joining the AWS Marketplace, Echoworx is taking this mission a step further, ensuring that customers can procure its encryp...
AFP’s 2024 financial results: turnover growth of 2 percent and positive net profits for sixth straight year
During its meeting on April 29, 2025, AFP’s board approved the 2024 accounts, which confirm the positive financial trajectory the Agency has been on for seven years.
The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic medical device in China. It is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy. This is the first Promega companion diagnostic to receive NMPA approval. “This approval represents a step ...